Explanation of how the number of participants for analysis was determined.
Includes whether analysis was per protocol, intention to treat, or another method.
Also provides relevant details such as imputation technique, as appropriate.

No text entered.

Reporting Groups

Description

Boostrix Group

Subjects received a single dose of Boostrix™ (tetanus toxoids, reduced diphtheria toxoids and acellular pertussis vaccine)

Decavac Group

Subjects received a single dose of Decavac™ (tetanus and diphtheria toxoids vaccine)

Explanation of how the number of participants for analysis was determined.
Includes whether analysis was per protocol, intention to treat, or another method.
Also provides relevant details such as imputation technique, as appropriate.

Analysis was performed on the According-To-Protocol (ATP) cohort for analysis of immunogenicity, on subjects with available results

Reporting Groups

Description

Boostrix Group

Subjects received a single dose of Boostrix™ (tetanus toxoids, reduced diphtheria toxoids and acellular pertussis vaccine)

Decavac Group

Subjects received a single dose of Decavac™ (tetanus and diphtheria toxoids vaccine)